| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Transactivator of transcription (TAT) cell-penetrating peptide.
|
|---|---|
| ln Vitro |
Not applicable as Biotin-TAT (47-57) is a cell-penetrating peptide delivery vehicle.
|
| Enzyme Assay |
In cultured primary cells (e.g., neurons, fibroblasts, immune cells), Biotin-TAT (47-57) at concentrations of 1-20 uM efficiently transports conjugated cargo into the cytoplasm and nucleus. After 1-4 hours of incubation, fluorescence microscopy reveals rapid cellular uptake. The biotin tag allows for detection or pull-down assays using streptavidin-conjugated probes (e.g., streptavidin-FITC or magnetic beads), facilitating the study of cargo delivery efficiency.
|
| Cell Assay |
A standard cell uptake assay: Incubate cells (e.g., HeLa, Jurkat, primary neurons) with 5-20 uM Biotin-TAT (47-57) in serum-free medium for 1-4 hours at 37degC. After incubation, wash cells three times with PBS to remove surface-bound peptide. Fix cells with 4% paraformaldehyde, permeabilize with 0.1% Triton X-100, and block with 5% BSA. Incubate with streptavidin-FITC (1:500) for 1 hour at room temperature. Counterstain nuclei with DAPI, mount, and image using confocal microscopy with appropriate filter sets.
|
| Animal Protocol |
For in vivo delivery studies, dissolve Biotin-TAT (47-57) in sterile PBS. Administer to mice via intravenous (IV) tail vein injection (5-20 mg/kg) or intraperitoneal (IP) injection. For brain targeting, intranasal administration is also effective. After 2-4 hours, perfuse animals with PBS, harvest tissues (brain, liver, spleen, kidney), and prepare frozen sections. Incubate sections with streptavidin-FITC or streptavidin-HRP to visualize TAT distribution. Biotin-TAT efficiently crosses the blood-brain barrier (BBB) and delivers cargo to brain parenchyma.
|
| ADME/Pharmacokinetics |
Based on its molecular weight (~1.8 kDa) and cationic peptide nature, Biotin-TAT (47-57) has a short plasma half-life (t1/2 ~5-15 min) due to rapid proteolytic degradation in the bloodstream. Despite its short half-life, efficient cargo delivery occurs quickly. Biodistribution studies show accumulation in liver, kidneys, and spleen, with significant accumulation in the brain following administration, likely due to adsorptive-mediated transcytosis across the BBB.
|
| Toxicity/Toxicokinetics |
At typical in vitro concentrations (10-50 uM for up to 4 hours), Biotin-TAT (47-57) shows low cytotoxicity (cell viability >80%) in most primary cell types. In vivo studies in mice at standard dosing (10-20 mg/kg IV) do not produce acute toxicity or mortality. However, at high concentrations (>100 uM or >50 mg/kg), non-specific membrane disruption and inflammatory responses may occur.
|
| References |
[1]. Chen Sun, et al. Intracellular tracking of single native molecules with electroporation-delivered quantum dots. Anal Chem. 2014 Nov 18;86(22):11403-9.
[2]. Jean Philippe Richard, et al. Cellular uptake of unconjugated TAT peptide involves clathrin-dependent endocytosis and heparan sulfate receptors. J Biol Chem. 2005 Apr 15;280(15):15300-6. |
| Additional Infomation |
Biotin-TAT (47-57) is a research tool for intracellular delivery and is not approved for human therapeutic use. It is widely used in drug delivery research to evaluate the efficacy of TAT-mediated transport of therapeutic cargo. The biotin tag provides a versatile platform for conjugation to a wide range of detection and purification systems, making it indispensable for mechanistic studies of cell-penetrating peptides and targeted drug delivery.
|
| Molecular Formula |
C74H132N34O16S
|
|---|---|
| Molecular Weight |
1786.12
|
| Exact Mass |
1785.028
|
| CAS # |
1231898-25-1
|
| PubChem CID |
168013077
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-10.5
|
| Hydrogen Bond Donor Count |
36
|
| Hydrogen Bond Acceptor Count |
25
|
| Rotatable Bond Count |
70
|
| Heavy Atom Count |
125
|
| Complexity |
3580
|
| Defined Atom Stereocenter Count |
13
|
| SMILES |
C1[C@H]2[C@@H]([C@@H](S1)CCCCC(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)NC(=O)N2
|
| InChi Key |
CABVDGGNWCCYNJ-NOQLBFJMSA-N
|
| InChi Code |
InChI=1S/C74H132N34O16S/c75-29-5-3-13-43(99-59(114)42(15-7-31-90-68(78)79)97-56(112)38-96-58(113)51(37-40-23-25-41(109)26-24-40)98-55(111)22-2-1-21-53-57-52(39-125-53)107-74(124)108-57)60(115)100-44(14-4-6-30-76)61(116)101-45(16-8-32-91-69(80)81)62(117)102-47(18-10-34-93-71(84)85)64(119)105-49(27-28-54(77)110)66(121)104-46(17-9-33-92-70(82)83)63(118)103-48(19-11-35-94-72(86)87)65(120)106-50(67(122)123)20-12-36-95-73(88)89/h23-26,42-53,57,109H,1-22,27-39,75-76H2,(H2,77,110)(H,96,113)(H,97,112)(H,98,111)(H,99,114)(H,100,115)(H,101,116)(H,102,117)(H,103,118)(H,104,121)(H,105,119)(H,106,120)(H,122,123)(H4,78,79,90)(H4,80,81,91)(H4,82,83,92)(H4,84,85,93)(H4,86,87,94)(H4,88,89,95)(H2,107,108,124)/t42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,57-/m0/s1
|
| Chemical Name |
(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]-6-aminohexanoyl]amino]-6-aminohexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-amino-5-oxopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.5599 mL | 2.7994 mL | 5.5987 mL | |
| 5 mM | 0.1120 mL | 0.5599 mL | 1.1197 mL | |
| 10 mM | 0.0560 mL | 0.2799 mL | 0.5599 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
